List of Excipients in Branded Drug PRAVASTATIN SODIUM

Generic Drugs Containing PRAVASTATIN SODIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	pravastatin sodium	0093-0771	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Teva Pharmaceuticals USA Inc	pravastatin sodium	0093-0771	ANHYDROUS LACTOSE
Teva Pharmaceuticals USA Inc	pravastatin sodium	0093-0771	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	pravastatin sodium	0093-0771	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	pravastatin sodium	0093-0771	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	pravastatin sodium	0093-0771	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in PRAVASTATIN SODIUM?

# Of NDCs	Excipient
6	ALCOHOL
2	ALUMINUM OXIDE
33	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
54	ANHYDROUS LACTOSE
1	BLUE 1
11	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS

Pravastatin Sodium Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Pravastatin sodium is a mature, multisource statin with limited molecule-level exclusivity and substantial room for product differentiation through formulation, packaging, adherence support, and manufacturing economics. The strongest commercial opportunities are low-cost robust tablets, lactose-free or allergen-controlled formulations, small-volume pediatric or dysphagia-oriented products, and fixed-dose cardiovascular combinations.

What is the commercial status of pravastatin sodium?

Pravastatin sodium is an orally administered HMG-CoA reductase inhibitor used to reduce LDL cholesterol and cardiovascular risk. The U.S. reference product is Pravachol, originally marketed by Bristol-Myers Squibb. FDA-approved tablet strengths are generally 10 mg, 20 mg, 40 mg, and 80 mg.[1]

Attribute	Pravastatin sodium
Therapeutic class	Statin lipid-lowering agent
Dosage form	Immediate-release oral tablet
U.S. reference product	Pravachol
Common strengths	10 mg, 20 mg, 40 mg, 80 mg
Regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable
Core patent position	Expired
Current market structure	Generic, multisource
Primary commercial pressure	Low price and high substitution
Main differentiation levers	Cost, excipient profile, swallowability, packaging, adherence, supply reliability

Pravastatin has a comparatively low interaction burden because it is not extensively metabolized by CYP3A4. That characteristic supports continued use in patients receiving multiple medicines, although commercial growth is constrained by competition from atorvastatin and rosuvastatin, which generally provide greater LDL reduction at comparable doses.[2]

What excipients are used in pravastatin sodium tablets?

Approved pravastatin sodium tablets commonly use a conventional direct-compression or wet-granulation excipient system. Representative inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and talc.[1,3]

Excipient category	Typical materials	Function
Diluent	Lactose monohydrate, microcrystalline cellulose	Tablet mass and compression
Binder	Povidone	Granule and tablet strength
Disintegrant	Croscarmellose sodium	Rapid tablet breakup
Lubricant	Magnesium stearate	Ejection and tooling protection
Glidant or coating aid	Talc, colloidal silicon dioxide	Flow and processing
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Identification, protection, swallowability

The exact inactive ingredient profile differs by manufacturer, strength, color system, and country. FDA labeling requires the specific excipient composition for each marketed product, so an ANDA sponsor should treat the reference product’s qualitative and quantitative excipient profile as a regulatory benchmark rather than assume that all pravastatin tablets use the same formulation.[1,4]

Is lactose a major excipient strategy issue?

Lactose is commercially relevant because it is common in immediate-release tablets and can reduce formulation cost. It also creates a differentiation opportunity for lactose-free products aimed at patients with lactose intolerance, dietary restrictions, or institutional procurement requirements.

A lactose-free formulation can replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or a combination of these materials. The replacement affects:

• Tablet weight and size
• Powder flow
• Compactability
• Disintegration
• Dissolution
• Moisture sensitivity
• Film-coating behavior
• Cost of goods

Lactose removal should not be positioned as a clinical improvement unless supported by clinical or patient-use data. It is primarily a formulation, labeling, procurement, and tolerability differentiation.

How should an excipient strategy be designed for pravastatin sodium?

The preferred strategy depends on the target market. A low-cost generic, a hospital product, and a premium adherence-oriented product require different excipient choices.

Strategy 1: Lowest-cost conventional tablet

The lowest-risk product uses widely available compendial excipients and a process compatible with standard high-speed tableting. Lactose and microcrystalline cellulose provide a cost-effective dilution system. Croscarmellose sodium supports rapid disintegration, while magnesium stearate provides routine lubrication.

This approach is appropriate when the commercial objective is:

• Fast ANDA development
• Minimal formulation complexity
• Low manufacturing cost
• Broad contract manufacturing compatibility
• Institutional and retail substitution

The main risks are commodity price exposure, tablet variability at low dose, and dependence on a conventional product profile that offers little differentiation.

Strategy 2: Lactose-free and excipient-controlled tablet

A lactose-free formulation can use microcrystalline cellulose and mannitol for a more neutral excipient profile. Mannitol can improve mouthfeel and reduce the perception of a chalky tablet, but it can increase cost and may require tighter control of particle size and compression conditions.

This strategy is attractive for:

• Retail private-label products
• E-commerce and direct-to-consumer pharmacy channels
• Patients reporting excipient sensitivities
• Hospital formularies with excipient restrictions
• International markets with different labeling preferences

The regulatory burden is manageable for an immediate-release ANDA if dissolution and bioequivalence requirements are met. The formulation should avoid unnecessary proprietary excipients because a mature molecule rarely supports enough price premium to justify high supply-chain complexity.

Strategy 3: Low-dose content-uniformity platform

The 10 mg strength presents a greater formulation challenge than the 40 mg or 80 mg strengths because the active ingredient represents a smaller fraction of tablet mass. A robust platform should focus on blend uniformity, segregation control, and assay precision.

Useful controls include:

• Narrow particle-size distribution for pravastatin sodium
• Geometric dilution or ordered mixing
• Low-segregation excipient grades
• Validated blend sampling
• Controlled lubricant addition
• Granulation when direct compression does not provide adequate uniformity

A common platform across 10 mg, 20 mg, 40 mg, and 80 mg strengths can reduce development and manufacturing complexity. The sponsor must still demonstrate strength-specific performance because tablet dimensions, compression force, dissolution, and dose proportionality may differ.

Strategy 4: Dysphagia-oriented or orally disintegrating product

Pravastatin sodium is a plausible low-dose candidate for an orally disintegrating tablet because the active dose is small. A product could use mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The main development barriers are:

• Bitter or medicinal taste
• Moisture sensitivity
• Friability
• Packaging cost
• Dose uniformity
• Rapid dissolution without excessive tablet hardness
• Demonstration of bioequivalence to the reference tablet

A conventional ODT may have limited commercial value because patients can already swallow a small immediate-release tablet. The opportunity is stronger in geriatric care, long-term-care facilities, dysphagia populations, and markets where adherence packaging supports premium reimbursement.

Strategy 5: Sprinkle or dispersible product

A capsule, granule, or dispersible tablet could target patients unable to swallow conventional tablets. Pravastatin sodium is chemically suited to an oral dosage-form platform, but a sprinkle product requires evaluation of:

• Taste after dispersion
• Dose recovery from food or liquid
• Stability after opening
• Compatibility with soft foods
• Uniform delivery from a single-dose sachet
• Labeling for administration with specific vehicles

This product would require a stronger clinical-use case than a standard generic tablet. It may be more commercially defensible in pediatric, geriatric, or institutional settings than in the general retail market.

What formulation patents could protect a pravastatin sodium product?

Pravastatin sodium’s original composition-of-matter and product exclusivity have expired. New patent value would therefore come from formulation, delivery, manufacturing, or use claims rather than the active ingredient itself.

Potential patent targets include:

Patent category	Example claim focus	Commercial value
ODT formulation	Porous tablet, rapid disintegration, taste masking	Moderate if clinical use is differentiated
Sprinkle formulation	Stable granules for food or liquid administration	Moderate
Stability formulation	Moisture-control system or impurity suppression	Moderate
Manufacturing process	Continuous blending, granulation, or compression process	Usually defensive
Packaging system	Moisture-barrier unit-dose packaging	Usually limited unless integrated with dosage form
Combination product	Pravastatin with antihypertensive or antiplatelet agent	Potentially high, subject to clinical value
Method of use	Selected patient subgroup or dosing regimen	Limited unless supported by meaningful data

A patent based only on substituting one ordinary diluent for another is unlikely to provide strong enforceability or meaningful market exclusion. Stronger claims would require measurable technical effects, such as improved stability, reduced impurity formation, superior dissolution under discriminatory conditions, or clinically meaningful adherence improvement.

When does pravastatin sodium lose exclusivity?

Pravastatin sodium lost meaningful U.S. molecule-level exclusivity years ago. Pravachol’s core patent estate is expired, and FDA-approved generic tablets are available through the ANDA pathway.[5]

Exclusivity issue	Current assessment
Composition-of-matter patent	Expired
Original product patent	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	Expired or no longer commercially relevant
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Generic substitution	Established
Current protection	Product-specific formulation or method patents, if any

The commercial question is not whether the active ingredient remains protected. It is whether a specific marketed product has a valid, unexpired formulation, process, or method-of-use right that could delay or complicate competition.

What is the Orange Book status of pravastatin sodium?

FDA’s Orange Book identifies approved reference and generic drug products and records patent and exclusivity information for listed products.[5] Pravachol and pravastatin sodium tablets are small-molecule products, not biologics. ANDA applicants generally use paragraph I, II, III, or IV certifications depending on the Orange Book patent record.

For a mature pravastatin product:

• A paragraph IV challenge is relevant only if an unexpired listed patent exists.
• A paragraph III certification can delay launch until patent expiration.
• If no relevant unexpired patent is listed, patent certification is not the principal launch barrier.
• Regulatory review, manufacturing readiness, and commercial pricing become more important than patent litigation.

Which companies are challenging pravastatin sodium patents?

No active patent challenge is central to the current pravastatin sodium market. Historical ANDA disputes would have concerned the expired Pravachol patent estate and are no longer the primary source of generic entry risk.

The competitive field is composed mainly of generic manufacturers and distributors, including large multisource suppliers, contract manufacturers, and private-label organizations. The principal competitive threat is price erosion rather than a new paragraph IV campaign.

Does pravastatin sodium have biosimilar risk?

No. Pravastatin sodium is a synthetic small molecule. Biosimilars apply to biological products. Competitive entry occurs through generic-drug applications, not the abbreviated pathway for biosimilars.

The relevant substitutes are:

• Generic pravastatin sodium
• Atorvastatin
• Rosuvastatin
• Simvastatin
• Fluvastatin
• Pitavastatin
• Combination lipid-lowering products

Atorvastatin and rosuvastatin create the strongest therapeutic and commercial pressure because they often deliver greater LDL reduction. Pravastatin retains a role where tolerability, interaction management, lower-intensity treatment, or patient history supports its use.[2]

What generic entry risks exist for pravastatin sodium?

Generic entry risk is already realized rather than prospective. The market has multiple suppliers, so a new entrant should expect rapid price comparison and limited protection from the active ingredient.

The main risks are:

1. Price compression from multisource competition.
2. Retail substitution away from branded or premium-priced products.
3. Supply interruptions caused by low-margin manufacturing.
4. Commodity excipient and packaging cost increases.
5. Shortages of qualified API or tablet manufacturing capacity.
6. Failure to achieve dissolution or bioequivalence across strengths.
7. Limited reimbursement for differentiated dosage forms.
8. Weak commercial uptake of a formulation that does not solve a clear patient problem.

The strongest entry case is a product with a defined channel advantage, such as a reliable hospital supply contract, a private-label arrangement, a lactose-free positioning, or a dysphagia-oriented dosage form.

What manufacturing and excipient barriers affect commercial launch?

Pravastatin sodium is not generally considered a high-barrier active ingredient, but manufacturing performance still affects profitability. Key technical controls include:

• API assay and impurity profile
• Particle-size distribution
• Moisture exposure
• Blend uniformity
• Lubrication time
• Tablet hardness and friability
• Dissolution across pH conditions
• Film-coat adhesion
• Packaging moisture protection
• Stability of the sodium salt under storage conditions

A standard tablet can use high-throughput equipment and established excipients. An ODT, sprinkle, or modified formulation requires additional process development and may need higher-cost packaging.

Excipient suppliers can capture value by providing:

• Direct-compression grades with consistent flow
• Low-moisture microcrystalline cellulose
• Co-processed excipients
• Mannitol grades optimized for mouthfeel
• Disintegrants with rapid liquid uptake
• Low-peroxide or low-metal excipient grades
• Film-coating systems with reduced processing time
• Excipient premixes that improve content uniformity

The best supplier proposition is measurable process improvement, not a novel ingredient without a validated benefit.

What licensing deals and commercial partnerships are relevant?

For a mature generic such as pravastatin sodium, licensing is more likely to involve distribution, private labeling, contract manufacturing, or combination-product rights than licensing of the core molecule.

Potential partnership structures include:

Partnership	Commercial purpose
Contract manufacturing	Reduce capital requirements and accelerate launch
Private-label supply	Access pharmacy, payer, or retail channels
Regional licensing	Enter markets with local registration and distribution support
Excipient supply agreement	Secure cost and quality for a differentiated formulation
Combination-product collaboration	Develop cardiovascular fixed-dose products
Hospital supply agreement	Improve volume visibility and manufacturing utilization

A licensing transaction would require a defensible product advantage. For a basic immediate-release tablet, the asset value is usually tied to regulatory approval, manufacturing reliability, channel access, and supply continuity rather than patent exclusivity.

How does pravastatin sodium compare with competing statins?

Drug	Relative potency	Generic competition	Formulation opportunity	Commercial position
Pravastatin	Lower to moderate	High	Moderate	Tolerability and interaction positioning
Simvastatin	Moderate	High	Moderate	Established, but safety and interaction limitations
Atorvastatin	High	High	Moderate	Large-volume, broad clinical use
Rosuvastatin	Very high	High	Moderate	Strong LDL reduction and premium generic demand
Pitavastatin	Moderate to high	Growing	Moderate	Smaller market, differentiated tolerability profile
Fluvastatin	Lower	Moderate	Limited	Niche use

Pravastatin’s excipient opportunity is therefore more important than its molecule-level patent opportunity. A technically simple product with dependable supply may outperform a heavily differentiated product if the target market is price-sensitive.

What is the revenue exposure and opportunity size?

Revenue exposure depends on the target market, strength mix, payer channel, and price strategy. The 40 mg strength is likely to be commercially important because it is a common maintenance dose. The 10 mg and 20 mg strengths support dose titration, while 80 mg addresses higher-dose treatment but faces competition from more potent statins.

Commercial opportunities include:

• High-volume low-cost generic tablets
• Multi-strength portfolios
• Unit-dose institutional packaging
• Lactose-free products
• Adherence blister packs
• Dysphagia-oriented dosage forms
• Regional private-label products
• Pravastatin-containing fixed-dose combinations

The strongest near-term business case is a conventional tablet platform with low manufacturing cost, reliable supply, and a differentiated excipient declaration. Premium delivery systems require evidence that the target population will pay for or receive reimbursement for the added functionality.

Key Takeaways

• Pravastatin sodium is a mature generic small molecule with no meaningful core-patent exclusivity.
• Biosimilar risk is irrelevant; generic competition is the governing market force.
• Conventional excipients such as lactose, microcrystalline cellulose, croscarmellose sodium, povidone, and magnesium stearate support a low-cost tablet.
• Lactose-free, low-moisture, ODT, sprinkle, and unit-dose products offer the clearest excipient-led differentiation.
• New patent value must come from demonstrated formulation, manufacturing, delivery, or method-of-use advantages.
• The 10 mg strength requires particular attention to content uniformity and segregation control.
• A low-cost, multi-strength product with dependable supply is likely to have a stronger return profile than a complex premium formulation.
• Licensing value is more likely to arise from manufacturing, distribution, private-label, or combination-product arrangements than from the pravastatin molecule.

FAQs

Can pravastatin sodium tablets be formulated without lactose?

Yes. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or co-processed excipients can replace lactose, subject to dissolution, stability, content-uniformity, and bioequivalence requirements.

Is pravastatin sodium suitable for an orally disintegrating tablet?

Yes, because the active dose is small. The commercial case depends on taste masking, friability control, moisture-protective packaging, and a defined dysphagia or adherence market.

Can an excipient change create a new pravastatin patent?

It can support a patent only if the formulation produces a novel and non-obvious technical result. A routine substitution of lactose with another diluent generally provides weak exclusivity.

Does pravastatin sodium require a paragraph IV strategy?

Only if an unexpired Orange Book-listed patent applies to the relevant reference product. For the mature pravastatin market, regulatory approval, manufacturing, and pricing are more significant than a new paragraph IV campaign.

Which pravastatin sodium product has the strongest commercial opportunity?

A low-cost, lactose-free, multi-strength tablet with robust content uniformity, high supply reliability, and institutional or private-label distribution is the most practical opportunity. An ODT or sprinkle product can command more differentiation but carries higher development, packaging, and market-adoption risk.

References

1. U.S. Food and Drug Administration. (2024). Pravastatin sodium tablets: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2018). FDA-approved drug products containing pravastatin sodium. FDA labeling and clinical pharmacology materials.
3. National Library of Medicine. (2024). DailyMed: Pravastatin sodium tablet inactive ingredients. DailyMed.
4. U.S. Food and Drug Administration. (2019). Inactive ingredient database guidance and database. FDA.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.